Annals of Oncology

Papers
(The H4-Index of Annals of Oncology is 94. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sid887
Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu840
1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients770
821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma644
LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, op612
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?605
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial551
ESMO pays tribute to Professor José Baselga485
588P Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial417
O8-4 Siteless study for feasibility of electronic patient-reported outcome (ePRO) collection system in oncology397
O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial392
111P A study on the relationship between tumor fusion burden (TFB) and tumor immune microenvironment375
118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella374
P-167 Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients366
140P Benefit of adjuvant chemotherapy in luminal A-like early breast cancer in women aged 40 years or younger: Results of a national multi-institutional study366
1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)360
P-111 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model337
P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy328
P-201 Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors316
JS5-5 Onco-cardiology: Collaboration and task sharing for oncologist and cardiologist313
801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma305
PSY1-5 Precision medicine in gynecological cancer287
839P Physician considered treatment attributes for third-line diffuse-large B-cell lymphoma treatment decision-making: Physician perspectives from a survey across Western Europe and US284
P-64 The impact of sarcopenia on overall survival among cholangiocarcinoma patients: A systematic review and meta-analysis283
1803P The differences of TMB scores could be found in patients with different tumor types or pathological types275
31P Sulfhydryl groups in estrogen receptors275
P-217 The knowledge and awareness for colorectal cancer in advanced colorectal cancer patients in China: A national multicenter study271
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data268
Notice and Disclaimer267
P-362 Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome258
P-379 ARID1A as a prognostic biomarker in gastroesophageal cancer: A genomic database analysis246
1692P Thromboprophylaxis in high-risk oncology patients: Is it a safe and effective clinical decision-intervention?217
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study215
1483P Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer211
1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study211
1482P Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients201
404P Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India200
1481P Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status198
50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients197
461P Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India196
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience196
720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence182
P30-10 Prevention of chemotherapy-induced peripheral neuropathy by compression therapy178
P49-4 Thyroid dysfunction associated with immune checkpoint blockade: An emerging immune-related adverse event175
1583P COVID-19 related risk in patients enrolled in early-phase clinical trials171
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)166
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial dis163
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study163
70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry162
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort 160
39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients159
P55-6 Encorafenib for Erdheim-Chester disease harboring the BRAFV600E mutation157
P53-4 Metastatic prostate cancer mimicking a rectal cancer: A case report157
347MO 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial157
P58-7 Aortitis after the use of granulocyte colony stimulating factors: A case of right lower gingival carcinoma157
651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)152
677P Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials147
355P Butterfly glioblastoma: Treatment strategies and clinical outcome146
P-7 How much can GIT cancer patients afford for effective and safe treatment?142
SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study142
P-160 Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up139
CN14 Cancer prevention awareness among Croatian AYA population137
CN28 Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization135
P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis134
83TiP Clinical implications of clonal hematopoiesis mutations in patients with solid tumors129
Journal Information128
P-177 Sex differences in chemotherapy-induced toxicities in gastric cancer patients128
P-184 Prognostic value of mTOR expression and mismatch repair gene profile in advanced gastric and gastro-oesophageal cancer125
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients124
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies119
MO9-8 Development of a data management system for comprehensive genomic profiling tests118
137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors116
1012P Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade116
1006P ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 116
139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal115
202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibito114
MO21-1 Prognostic value of pneumonitis after durvalumab in locally-advanced non-small cell lung cancer113
O7-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16113
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy112
37P Development of splice switching antisense oligonucleotides targeting midkine110
121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data109
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1108
140P Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience107
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study106
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy105
Title Page103
12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer103
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation103
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis102
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data102
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer102
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the 101
554P Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study99
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized tria94
0.069858074188232